Cargando…

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling

Src family tyrosine kinase (SFK) activation is associated with ovarian cancer progression. Therefore, SFKs are targets for the development of potential treatments of ovarian cancer. Dasatinib is a tyrosine kinase inhibitor that targets SFK activity, and is used for the treatment of B cell and Abelso...

Descripción completa

Detalles Bibliográficos
Autores principales:	XIAO, JUAN, XU, MANMAN, HOU, TENG, HUANG, YONGWEN, YANG, CHENLU, LI, JUNDONG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526065/ https://www.ncbi.nlm.nih.gov/pubmed/25975261 http://dx.doi.org/10.3892/mmr.2015.3784

Ejemplares similares

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
por: Kadife, Elif, et al.
Publicado: (2019)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling
por: WU, JIANGHONG, et al.
Publicado: (2013)

Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer
por: Wang, Taiwei, et al.
Publicado: (2022)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
por: Sun, Jingya, et al.
Publicado: (2018)

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429
por: Guo, Qinglong, et al.
Publicado: (2018)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
por: Dosch, Austin R., et al.
Publicado: (2019)

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype
por: Kurebayashi, Junichi, et al.
Publicado: (2010)

Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells
por: Chen, Bin, et al.
Publicado: (2015)

miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
por: Xu, Manman, et al.
Publicado: (2018)

Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro
por: Song, Yan, et al.
Publicado: (2013)

A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance
por: Li, Jun, et al.
Publicado: (2017)

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
por: Id Boufker, Hichame, et al.
Publicado: (2010)

Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
por: Takiguchi, Eri, et al.
Publicado: (2017)

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
por: Ocana, Alberto, et al.
Publicado: (2017)

Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo
por: Yang, Lu, et al.
Publicado: (2021)

Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
por: Kim, Seongyeong, et al.
Publicado: (2017)

HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib
por: deBlacam, C, et al.
Publicado: (2011)

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
por: Scott, Aaron J., et al.
Publicado: (2017)

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
por: Lee, Dajeong, et al.
Publicado: (2020)

Endothelial VEGFR2-PLCγ signaling regulates vascular permeability and antitumor immunity through eNOS/Src
por: Sjöberg, Elin, et al.
Publicado: (2023)

Tetramethylpyrazine Enhances the Antitumor Effect of Paclitaxel by Inhibiting Angiogenesis and Inducing Apoptosis
por: Zou, Liang, et al.
Publicado: (2019)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042
por: Hermida-Prado, Francisco, et al.
Publicado: (2019)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation
por: Fu, Yang, et al.
Publicado: (2018)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation
por: Pan, Rulu, et al.
Publicado: (2022)

Epithelial-Mesenchymal Transition of Ovarian Cancer Cells Is Sustained by Rac1 through Simultaneous Activation of MEK1/2 and Src Signaling Pathways
por: Fang, Dongdong, et al.
Publicado: (2016)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

Hyaluronan Oligosaccharides-Coated Paclitaxel-Casein Nanoparticles with Enhanced Stability and Antitumor Activity
por: Wang, Man, et al.
Publicado: (2022)

Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging
por: Nobis, Max, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aaiugcme01m7gmklbtj20bco2b